Interferon-alpha-induced agranulocytosis in a patient on long-term clozapine therapy. 1998

R M Hoffmann, and S Ott, and K G Parhofer, and R Bartl, and G R Pape

UI MeSH Term Description Entries
D008297 Male Males
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000075202 Contraindications A condition or factor associated with a recipient that makes the use of a drug, procedure, or physical agent improper or inadvisable. Contraindications may be absolute (life threatening) or relative (higher risk of complications in which benefits may outweigh risks). Contraindications, Physical Agent,Medical Contraindications,Agent Contraindication, Physical,Agent Contraindications, Physical,Contraindication,Contraindication, Medical,Contraindication, Physical Agent,Contraindications, Medical,Medical Contraindication,Physical Agent Contraindication,Physical Agent Contraindications
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000380 Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia,Agranulocytoses,Granulocytopenias
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

R M Hoffmann, and S Ott, and K G Parhofer, and R Bartl, and G R Pape
March 2006, Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999),
R M Hoffmann, and S Ott, and K G Parhofer, and R Bartl, and G R Pape
May 2003, International clinical psychopharmacology,
R M Hoffmann, and S Ott, and K G Parhofer, and R Bartl, and G R Pape
May 2006, Psychiatrische Praxis,
R M Hoffmann, and S Ott, and K G Parhofer, and R Bartl, and G R Pape
November 2025, International clinical psychopharmacology,
R M Hoffmann, and S Ott, and K G Parhofer, and R Bartl, and G R Pape
January 2008, Psychosomatics,
R M Hoffmann, and S Ott, and K G Parhofer, and R Bartl, and G R Pape
January 1994, Harefuah,
R M Hoffmann, and S Ott, and K G Parhofer, and R Bartl, and G R Pape
November 2020, Annals of hematology,
R M Hoffmann, and S Ott, and K G Parhofer, and R Bartl, and G R Pape
January 1987, Blut,
R M Hoffmann, and S Ott, and K G Parhofer, and R Bartl, and G R Pape
December 1996, The Australian and New Zealand journal of psychiatry,
R M Hoffmann, and S Ott, and K G Parhofer, and R Bartl, and G R Pape
June 2016, European journal of rheumatology,
Copied contents to your clipboard!